Monoclonal Anti- Apolipoprotein A1, APOA1 antibody

Apolipoprotein A-I (APOA1) is the major protein component of high density lipoprotein (HDL) in plasma.[1]Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream.[2]It was composed of an N-terminal 4-helix bundle with a hydrophobic core and 2 C-terminal helices.[3]It has an approximate molecular weight of 28 KDa. A G/A polymorphism in the promoter of the ApoA-I gene has been associated with the age at which patients presented with Alzheimer disease.[4]Protection from Alzheimer disease by ApoA1 may rely on a synergistic interaction with alpha-tocopherol.[5]

Western Blot, WB (1:200-1:500) ; Immunohistochemistry, IHC-P (1:20-1:100) ; Immunocytochemistry, ICC (1:20-1:100) ; Flow Cytometry, Flow-Cyt (1:20-1:50)

Breslow, J. L., Ross, D., McPherson, J., Williams, H., Kurnit, D., Nussbaum, A. L., Karathanasis, S. K., Zannis, V. I. Isolation and characterization of cDNA clones for human apolipoprotein A-I. Proc. Nat. Acad. Sci. 79: 6861-6865, 1982. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ (january 2008) . "Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery". Nature Reviews Drug Discovery 7 (1) : 84–99. Ajees, A. A., Anantharamaiah, G. M., Mishra, V. K., Hussain, M. M., Murthy, H. M. K. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc. Nat. Acad. Sci. 103: 2126-2131, 2006. Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, Schulz A, Maier W, Kölsch H (2005) . "APOA1 polymorphism influences risk for early-onset nonfamiliar AD". Ann. Neurol. 58 (3) : 436–41. Maezawa I, Jin LW, , Montine TJ, Montine KS (2004) . "Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity". J. Neurochem. 91 (6) : 1312–21.